Comparative Pharmacology
Head-to-head clinical analysis: NORINYL versus NORINYL 1 50 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL versus NORINYL 1 50 21 DAY.
NORINYL vs NORINYL 1+50 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
None Documented
None Documented
Terminal half-life: norethindrone 7-8 hours, ethinyl estradiol 13-27 hours; clinical context: steady-state achieved in 3-5 half-lives
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Renal: ~60% as metabolites, biliary/fecal: ~40% as glucuronide conjugates
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive